|Application ||WB, IHC-P, E|
|Calculated MW||74605 Da|
|Purification||Antisera to DLL4 were raised by repeated immunisations of rabbits with highly purified antigen. Purified IgG was prepared by affinity chromatography.|
|Immunogen||Synthetic peptide corresponding to the internal region of human DLL4.|
|Shelf Life||18 months from date of despatch.|
|Other Names||Delta-like protein 4, Drosophila Delta homolog 4, Delta4, DLL4|
|Target/Specificity||Rabbit anti-Human Delta-like Protein 4 antibody detects human Delta-like protein 4 (DLL4), also known as Delta-4. DLL4 is a 685 amino acid single pass type 1 transmembrane glycoprotein of ~72kDa containing a single DSL domain and eight EGF-like domains. Human DLL4 is the homologue of the Drosophila delta protein, and functions as a transmembrane bound ligand to the Notch receptor Notch1.DLL4 is expressed in the vasculature and plays a critical role in vascular development. It is induced by vascular endothelial growth factor (VEGF), as a negative feedback regulator to regulate angiogenic sprouting and promote the formation of a differentiated vascular network (Mailhoset al.2001). DLL4 has been found to be strongly expressed in tumour vessels of primary renal tumours (Patelet al.2005) and bladder cancer (Patelet al.2006), and inhibition of DLL4 results in increased vascular proliferation but defective maturation. This in turn leads to a decrease in tumour growth, with no apparent toxicity (Ridgwayet al.2006).Expression of DLL4 in normal human dermis is low in foetal tissues, becomes more intense during early life (0-20 years) and gradually declines thereafter as shown by immunohistochemical studies on FFPE tissues using rabbit anti-human DLL4 antibody (Guninet al.2014).|
|Preservative & Stabilisers||0.09% Sodium Azide (NaN3)|
|Storage||Store at +4℃ or at -20 ℃.|
|Precautions||Anti-Human Delta-Like Protein 4 Antibody is for research use only and not for use in diagnostic or therapeutic procedures.|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
1. You, C. et al. (2013) Loss of CCM3 impairs DLL4-Notch signalling: implication in endothelial angiogenesis and in inherited cerebral cavernous malformations.J Cell Mol Med. 17 (3): 407-18. 2. Villaamil, V.M. et al. (2012) Multiple biomarker tissue arrays: A computational approach to identifying protein-protein interactions in the EGFR/ERK signalling pathway.J Mol Signal. 7: 14. 3. Gunin, A.G. et al. (2014) Age-related changes in angiogenesis in human dermis.Exp Gerontol. 55C: 143-51. 4. El Hindy, N. et al. (2013) Implications of Dll4-Notch signaling activation in primary glioblastoma multiforme.Neuro Oncol. 15: 1366-78. 5. Medina Villaamil, V. et al. (2012) Searching for Hif1-a interacting proteins in renal cell carcinoma.Clin Transl Oncol. 14: 698-708. 6. Gunin, A.G. et al. (2014) Age-related changes in angiogenesis in human dermis.Exp Gerontol. 55: 143-51.1. Thurston, G. et al. (2007) The Delta paradox: DLL4 blockade leads to more tumour vessels but less tumour growth.Nat Rev Cancer. 7 (5): 327-31.
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at email@example.com.